Juno Therapeutics Inc (JUNO) EVP Sells $1,998,677.91 in Stock

Juno Therapeutics Inc (NASDAQ:JUNO) EVP Robert Azelby sold 29,131 shares of the firm’s stock in a transaction dated Wednesday, January 17th. The shares were sold at an average price of $68.61, for a total value of $1,998,677.91. Following the completion of the sale, the executive vice president now directly owns 73,330 shares in the company, valued at $5,031,171.30. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Robert Azelby also recently made the following trade(s):

  • On Monday, December 18th, Robert Azelby sold 1,816 shares of Juno Therapeutics stock. The shares were sold at an average price of $44.96, for a total value of $81,647.36.
  • On Thursday, November 2nd, Robert Azelby sold 6,666 shares of Juno Therapeutics stock. The shares were sold at an average price of $54.95, for a total value of $366,296.70.

Juno Therapeutics Inc (JUNO) traded down $3.56 during midday trading on Friday, hitting $67.81. 5,220,193 shares of the company traded hands, compared to its average volume of 3,350,000. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics Inc has a twelve month low of $19.07 and a twelve month high of $74.35. The company has a market capitalization of $7,740.00, a PE ratio of -20.00 and a beta of 2.32.

Juno Therapeutics (NASDAQ:JUNO) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million during the quarter, compared to analysts’ expectations of $18.12 million. During the same quarter last year, the company earned ($0.57) earnings per share. The firm’s revenue was up 115.4% on a year-over-year basis. sell-side analysts predict that Juno Therapeutics Inc will post -4.02 earnings per share for the current year.

Several brokerages have recently issued reports on JUNO. Wells Fargo & Co reaffirmed a “market perform” rating and issued a $63.00 price target (up from $54.00) on shares of Juno Therapeutics in a research report on Wednesday. Zacks Investment Research downgraded Juno Therapeutics from a “hold” rating to a “sell” rating in a research report on Wednesday. Raymond James Financial reaffirmed a “buy” rating on shares of Juno Therapeutics in a research report on Wednesday. Wedbush downgraded Juno Therapeutics from an “outperform” rating to a “neutral” rating in a research report on Wednesday. Finally, JPMorgan Chase & Co. reaffirmed a “hold” rating on shares of Juno Therapeutics in a research report on Thursday, January 11th. Three research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Hold” and an average target price of $47.26.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Teachers Advisors LLC lifted its stake in Juno Therapeutics by 15.4% during the second quarter. Teachers Advisors LLC now owns 74,255 shares of the biopharmaceutical company’s stock worth $2,219,000 after purchasing an additional 9,890 shares during the period. DekaBank Deutsche Girozentrale lifted its stake in Juno Therapeutics by 27.9% during the third quarter. DekaBank Deutsche Girozentrale now owns 61,900 shares of the biopharmaceutical company’s stock worth $1,712,000 after purchasing an additional 13,500 shares during the period. Northern Trust Corp lifted its stake in Juno Therapeutics by 11.8% during the second quarter. Northern Trust Corp now owns 382,631 shares of the biopharmaceutical company’s stock worth $11,438,000 after purchasing an additional 40,468 shares during the period. Candriam Luxembourg S.C.A. bought a new position in Juno Therapeutics during the third quarter worth about $5,428,000. Finally, Sivik Global Healthcare LLC bought a new position in Juno Therapeutics during the third quarter worth about $2,467,000. Institutional investors and hedge funds own 69.94% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Juno Therapeutics Inc (JUNO) EVP Sells $1,998,677.91 in Stock” was reported by American Banking News and is the property of of American Banking News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.americanbankingnews.com/2018/01/19/juno-therapeutics-inc-juno-evp-sells-1998677-91-in-stock.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Insider Buying and Selling by Quarter for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply